Arpida Provides Comprhensive Overview of Pivotal Phase III ... (a Ltd. Arpida (SWX: ARPN) is a biopha...)

Arpida Provides Comprhensive Overview of Pivotal Phase III Trial Data

Date:4/17/2008

a Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent antibacterial that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The clinical programme for the first indication, complicated skin and skin structure infections (cSSSI), has been completed. The submission of the NDA to the US FDA was completed in March 2008.

In December 2007, Arpida announced the enrolment of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In January 2008, the US FDA granted authorisation to progress oral iclaprim into a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch could be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be effe
'/>"/>

SOURCE Arpida
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine news :

1. Study provides hope that some transplant patients could live free of antirejection drugs
2. Study provides hope that some transplant patients could live free of anti-rejection drugs
3. USAID Provides Additional Wildfire Assistance to Greece
4. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
5. New knock-out gene model provides molecular clues to breast cancer
6. PreMD Provides Update on 510(k) Application for PREVU(x) POC
7. SIV infection of natural hosts provides new insights into HIV disease complexity
8. Microarray provides 3 genomic guides to breast cancer treatment decisions
9. Access Innovations Provides Support Services for Agis Network
10. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
11. Physical Therapist Provides Injury Analysis for Fantasy Football

Post Your Comments:

(Date:5/26/2013)... Beautologie ( http://www.beautologie.com ), a leading ... Malibu and Fresno, has recently been honored for the ... “Best of Bakersfield” Award, and has also been highlighted ... “Best of Bakersfield” Award is based on nominations and ... businesses in the area. As such, the award is ...

(Date:5/26/2013)... 2013 http://www.resource4thepeople.com/defectivedrugs/nuvaring.html , ... an important hearing scheduled in consolidated federal NuvaRing ... contraceptive suffered serious blood-clotting side effects. , The ... hearing for June 21, 2013 at which lawyers ... NuvaRing defense attorneys will inform the judge about ...

(Date:5/25/2013)... NY (PRWEB) May 25, 2013 Country music fans ... Aldean's opening act in 2012. Due to overwhelming demand, Luke ... during 2013. , Luke Bryan has written successful songs ... nearly a decade ago back in the mid-2000 era. Some ... and Travis Tritt. , When Luke was 14, his parents ...

(Date:5/25/2013)... 25, 2013 According to an article in ... a Feeling,” nearly 30 million Americans tan indoors each year ... despite knowing the health risks. New research suggests ... addictive effect on the brains of some tanners (Go to ... article so I can’t say that I fully support this ...

(Date:5/25/2013)... It's not astonishing that holidays are amongst the ... endless, from family, friends and co-workers. Between the parties ... than their parents can afford, parties to arrange, and ... birthdays, anniversaries and it seems like an eternal cycle ... tired and income can’t catch up to the expenses ...

Breaking Medicine News(10 mins):Health News:Beautologie Wins Best of Bakersfield Award for 9th Year Running 2 Health News:Alleged NuvaRing Blood-Clotting Lawsuits Update: Resource4thePeople Reports Important Hearing Scheduled for July 2 Health News:Alleged NuvaRing Blood-Clotting Lawsuits Update: Resource4thePeople Reports Important Hearing Scheduled for July 3 Health News:Alleged NuvaRing Blood-Clotting Lawsuits Update: Resource4thePeople Reports Important Hearing Scheduled for July 4 Health News:Luke Bryan Tickets: Prices Slashed on Luke Bryan Tickets in Raleigh, Bethel, Camden, Peoria, Nashville, Hartford, Chicago, Boston, Atlanta, Indianapolis & SaratogaSprings 2 Health News:Sun Damage – Are UV Rays Addictive? 2 Health News:TheBeautyPlace.com Debuts Their Brand New Beauty Kits 2

[0] Beautologie Wins Best of Bakersfield Award for 9th Year Running [0] Alleged NuvaRing Blood-Clotting Lawsuits Update: Resource4thePeople Reports Important Hearing Scheduled for July [0] Luke Bryan Tickets: Prices Slashed on Luke Bryan Tickets in Raleigh, Bethel, Camden, Peoria, Nashville, Hartford, Chicago, Boston, Atlanta, Indianapolis & SaratogaSprings [0] Sun Damage – Are UV Rays Addictive?[0] TheBeautyPlace.com Debuts Their Brand New Beauty Kits

... hearing loss in laboratory animals, according to two new ... of a pill that could stave off noise-induced and ... findings will be reported Wednesday at the Association for ... author Colleen Le Prell, Ph.D., a researcher at the ...

... National Head Start Association (NHSA) issued the following statement ... is the director of the Albina Head Start program ... be created -- and more than 200,000 existing jobs ... has signed into law the economic recovery package containing ...

... Quarterly EPS of $0.39, Total Revenues of $109.1 Million ... Total Revenues by 17% -- Company Generates $178.3 Million ... Gen-Probe Incorporated (Nasdaq: GPRO ... quarter and full year ended December 31, 2008, including ...

... MADISON, Wis., Feb. 17 /PRNewswire-FirstCall/ -- Cogdell ... appointment of Roger Herritz as President of the Midwest ... Inpatient Project Delivery for the Company,s wholly owned subsidiary, ... the Company,s Madison office, Mr. Herritz will be responsible ...

... Lingering physical effects of cancer a likely cause, finds study, ... fighting cancer wasn,t hard enough, a new Dutch study concludes ... be able to find a job. , The meta-analysis of ... those who,d battled cancer were out of work vs. 15.2 ...

... sent today to,President Obama and members of the ... leadership of Congress on the enactment of,the American ... the first time,provides financial incentives to physicians who ... improve both the quality and cost-,effectiveness of patient ...

Vitamin supplements may protect against noise-induced hearing loss NHSA: President Obama, Congress Deserve High Praise for $2.1 Billion in Recovery Package for Head Start Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008 Cogdell Spencer Names Herritz and Wolters to Key Leadership Positions Within Erdman One in Three Cancer Survivors on Unemployment Line Allscripts Applauds Economic Stimulus Incentives Rewarding Physicians for Using Electronic Health Records

(Date:5/24/2013)... Corporation (NASDAQ: HSKA, "Heska" or the "Company"), a leading provider ... Robert Grieve , the Company,s chairman and ... executive vice president and chief financial officer, will present at ... May 30, 2013 in New York City ... Company,s presentation is scheduled to begin at 1:30 p.m. EDT. ...

(Date:5/24/2013)... Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL ) ... Deutsche Bank Health Care Conference to be held May ... Adrian Adams , Chief Executive Officer and ... Company and its product pipeline at 12:00 p.m. ET ... http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) The presentation will also ...

(Date:5/24/2013)... Sinovac Biotech Ltd. (NASDAQ: SVA ... China , announced that Sinovac ... obtained the Certificate of Good Manufacturing Practices for ... and Food Administration (CFDA) for its proprietary vaccines, ... Changping filing and packaging facility. The GMP certificate ...

Breaking Medicine Technology:Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2 Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2 Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3 Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4 Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 2 Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 3

[0] Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference [0] Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference [0] Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines

... bioTheranostics, a bioMerieux company,that discovers, develops and commercializes ... from three studies using the company,s,molecular breast cancer ... patients. Data from the studies were presented this ... , The ...

... from two early,clinical studies show that RAD001(R) (everolimus) may ... breast,cancer. These results support the initiation of a Phase ... RAD001 (proposed brand name,Afinitor(R)) in breast cancer. , ... were presented today during the CTRC-AACR San Antonio,Breast Cancer ...

Cached Medicine Technology:Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium 2 Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium 3 Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium 4 RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial 2 RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial 3 RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial 4 RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial 5 RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial 6 RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial 7

Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial

Hubbed drains are made of translucent silicone and include a full-length X-ray opaque stripe....

Siliconized PVC drains...

Bard® Channel Drain...

Used for placement of cholangiography catheters and other instruments. Supplied sterile in peel-open packages. Intended for one-time use....

Medicine Products:

Silicone Flat Hubbed Drains: 8 in. drains, 5.4 in. hole pattern Siliconized PVC drains Bard® Channel Drain Trocar Sheath Needle